The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00109408




Registration number
NCT00109408
Ethics application status
Date submitted
27/04/2005
Date registered
28/04/2005
Date last updated
2/11/2016

Titles & IDs
Public title
A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis
Scientific title
A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Monotherapy Versus Methotrexate Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis
Secondary ID [1] 0 0
WA17824
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Methotrexate
Treatment: Drugs - tocilizumab [RoActemra/Actemra]

Experimental: 1 -

Active Comparator: 2 -


Treatment: Drugs: Methotrexate
7.5-20mg po weekly

Treatment: Drugs: tocilizumab [RoActemra/Actemra]
8mg/kg iv every 4 weeks

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of patients with ACR 20 response
Timepoint [1] 0 0
Week 24
Secondary outcome [1] 0 0
Percentage of patients with ACR 20 response
Timepoint [1] 0 0
Week 8
Secondary outcome [2] 0 0
Percentage of patients with ACR 50 and ACR 70 responses
Timepoint [2] 0 0
Week 24
Secondary outcome [3] 0 0
Mean change in parameters of ACR core set
Timepoint [3] 0 0
Week 24
Secondary outcome [4] 0 0
AEs, laboratory parameters, vital signs.
Timepoint [4] 0 0
Throughout study

Eligibility
Key inclusion criteria
- adult patients at least 18 years of age with active RA for at least 3 months;

- patients of reproductive potential must be using reliable methods of contraception.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- major surgery (including joint surgery) within 8 weeks before entering study or
planned major surgery within 6 months after entering study;

- treatment with methotrexate (MTX) within 6 months of entering study;

- patients who have stopped previous MTX treatment due to toxicity or lack of response;

- women who are pregnant or breast-feeding.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Hobart
Recruitment hospital [3] 0 0
- Shenton Park
Recruitment hospital [4] 0 0
- Sydney
Recruitment hospital [5] 0 0
- Woodville
Recruitment hospital [6] 0 0
- Woolloongabba
Recruitment postcode(s) [1] 0 0
5041 - Adelaide
Recruitment postcode(s) [2] 0 0
7000 - Hobart
Recruitment postcode(s) [3] 0 0
6008 - Shenton Park
Recruitment postcode(s) [4] 0 0
2050 - Sydney
Recruitment postcode(s) [5] 0 0
5011 - Woodville
Recruitment postcode(s) [6] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Mississippi
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
New Hampshire
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oklahoma
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
South Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
Tennessee
Country [27] 0 0
United States of America
State/province [27] 0 0
Texas
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
Argentina
State/province [30] 0 0
Buenos Aires
Country [31] 0 0
Argentina
State/province [31] 0 0
Florencio Varela
Country [32] 0 0
Argentina
State/province [32] 0 0
Rosario
Country [33] 0 0
Canada
State/province [33] 0 0
British Columbia
Country [34] 0 0
Canada
State/province [34] 0 0
Manitoba
Country [35] 0 0
Canada
State/province [35] 0 0
Newfoundland and Labrador
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
China
State/province [37] 0 0
Guangzhou
Country [38] 0 0
China
State/province [38] 0 0
Hefei Anhui
Country [39] 0 0
China
State/province [39] 0 0
Jinan
Country [40] 0 0
Denmark
State/province [40] 0 0
Hillerod
Country [41] 0 0
Denmark
State/province [41] 0 0
Hvidovre
Country [42] 0 0
Denmark
State/province [42] 0 0
København
Country [43] 0 0
France
State/province [43] 0 0
Brest
Country [44] 0 0
France
State/province [44] 0 0
Lyon
Country [45] 0 0
France
State/province [45] 0 0
Paris
Country [46] 0 0
France
State/province [46] 0 0
Rouen
Country [47] 0 0
Israel
State/province [47] 0 0
Ashkelon
Country [48] 0 0
Israel
State/province [48] 0 0
Beer Sheva
Country [49] 0 0
Israel
State/province [49] 0 0
Haifa
Country [50] 0 0
Israel
State/province [50] 0 0
Kfar Saba
Country [51] 0 0
Israel
State/province [51] 0 0
Ramat Gan
Country [52] 0 0
Israel
State/province [52] 0 0
Rishon Lezion
Country [53] 0 0
Italy
State/province [53] 0 0
Genova
Country [54] 0 0
Italy
State/province [54] 0 0
Milano
Country [55] 0 0
Italy
State/province [55] 0 0
Pavia
Country [56] 0 0
Italy
State/province [56] 0 0
Reggio Emilia
Country [57] 0 0
Italy
State/province [57] 0 0
Siena
Country [58] 0 0
Lithuania
State/province [58] 0 0
Kaunas
Country [59] 0 0
Lithuania
State/province [59] 0 0
Klaipeda
Country [60] 0 0
Lithuania
State/province [60] 0 0
Panevezys
Country [61] 0 0
Lithuania
State/province [61] 0 0
Siauliai
Country [62] 0 0
Lithuania
State/province [62] 0 0
Vilnius
Country [63] 0 0
Mexico
State/province [63] 0 0
Guadalajara
Country [64] 0 0
Mexico
State/province [64] 0 0
Mexico City
Country [65] 0 0
Norway
State/province [65] 0 0
Levanger
Country [66] 0 0
Norway
State/province [66] 0 0
Lillehammer
Country [67] 0 0
Peru
State/province [67] 0 0
Lima
Country [68] 0 0
Portugal
State/province [68] 0 0
Almada
Country [69] 0 0
Portugal
State/province [69] 0 0
Lisboa
Country [70] 0 0
Serbia
State/province [70] 0 0
Belgrade
Country [71] 0 0
Serbia
State/province [71] 0 0
Niska Banja
Country [72] 0 0
Slovenia
State/province [72] 0 0
Ljubljana
Country [73] 0 0
Slovenia
State/province [73] 0 0
Maribor
Country [74] 0 0
South Africa
State/province [74] 0 0
Cape Town
Country [75] 0 0
South Africa
State/province [75] 0 0
Diepkloof
Country [76] 0 0
South Africa
State/province [76] 0 0
Pinelands
Country [77] 0 0
South Africa
State/province [77] 0 0
Radiokop
Country [78] 0 0
Spain
State/province [78] 0 0
Alcorcon
Country [79] 0 0
Spain
State/province [79] 0 0
Barcelona
Country [80] 0 0
Spain
State/province [80] 0 0
Córdoba
Country [81] 0 0
Spain
State/province [81] 0 0
Guadalajara
Country [82] 0 0
Spain
State/province [82] 0 0
La Laguna
Country [83] 0 0
Spain
State/province [83] 0 0
Lugo
Country [84] 0 0
Spain
State/province [84] 0 0
Salamanca
Country [85] 0 0
Spain
State/province [85] 0 0
Santiago de Compostela
Country [86] 0 0
Spain
State/province [86] 0 0
Valencia

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This 2 arm study will assess the safety and efficacy of tocilizumab monotherapy versus
methotrexate in patients with active rheumatoid arthritis (RA). Patients will be randomized
to receive tocilizumab 8mg/kg iv every 4 weeks plus placebo po weekly, or methotrexate
7.5-20mg po weekly plus placebo iv every 4 weeks. The anticipated time on study treatment is
3-12 months and the target sample size is 500+ individuals.
Trial website
https://clinicaltrials.gov/show/NCT00109408
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications